CTI Molecular Imaging Acquires Concorde Microsystems

CTI Molecular Imaging, Inc. (Knoxville, TN, USA), a provider of positron emission topography (PET) units and molecular imaging biomarkers and services, has agreed to acquire Concorde Microsystems, Inc. (Knoxville, TN, USA).

Concorde Microsystems provides small animal PET systems for imaging laboratory animals used in medical research. The acquisition will increase the capabilities of CT Molecular Imaging to broadly serve the research and pharmaceutical fields, and the company intends to leverage the acquisition of Concorde to accelerate the discovery of new molecular imaging biomarkers for the clinical market.

"This is another step in CTI Molecular Imaging's evolution toward a focus on developing new molecular probes and biomarkers for the diagnostic market. We intend to augment our own internal development of these compounds through partnerships with the leading pharmaceutical research organizations in the world,” said Thomas J. Hook, president of CTI Solutions and senior vice president of CTI Molecular Imaging.




Related Links:
CTI Molecular Imaging
Concorde Microsystems